{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:11:57Z","timestamp":1790856717345,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016807","name":"Natural Science Foundation of Shenyang Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.heliyon.2024.e33417","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T01:41:39Z","timestamp":1719020499000},"page":"e33417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adverse events associated with eteplirsen: A disproportionality analysis using the 2016\u20132023 FAERS data"],"prefix":"10.1016","volume":"10","author":[{"given":"Zhicheng","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e33417_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169176","article-title":"Full-length dystrophin restoration via targeted exon addition in DMD-patient specific iPSCs and cardiomyocytes","volume":"23","author":"Xiao","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e33417_bib2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.heliyon.2024.e33417_bib3","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jacbts.2019.06.006","article-title":"Gene therapy rescues cardiac dysfunction in Duchenne muscular dystrophy mice by elevating cardiomyocyte deoxy-adenosine triphosphate","volume":"4","author":"Kolwicz","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.heliyon.2024.e33417_bib4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.heliyon.2024.e33417_bib5","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","article-title":"Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK)","volume":"21","author":"Moat","year":"2013","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.heliyon.2024.e33417_bib6","first-page":"1","article-title":"An observational study on the safety of teprotumumab based on FAERS database","author":"Wang","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.heliyon.2024.e33417_bib7","series-title":"Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"10.1016\/j.heliyon.2024.e33417_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.addr.2015.05.008","article-title":"Exon skipping therapy for Duchenne muscular dystrophy","volume":"87","author":"Kole","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2024.e33417_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.heliyon.2024.e33417_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.heliyon.2024.e33417_bib11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","article-title":"Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA adverse event reporting system (FAERS) database","volume":"45","author":"Fusaroli","year":"2022","journal-title":"Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e33417_bib12","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/14740338.2023.2223958","article-title":"Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System","volume":"22","author":"Battini","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.heliyon.2024.e33417_bib13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e33417_bib14","article-title":"Association between blood lead level with high blood pressure in US (NHANES 1999-2018)","volume":"10","author":"Huang","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.heliyon.2024.e33417_bib15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40264-023-01345-w","article-title":"Challenges and opportunities in accessing and analysing FAERS data: a call towards a collaborative approach","volume":"46","author":"Giunchi","year":"2023","journal-title":"Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e33417_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jclinepi.2021.06.022","article-title":"High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study","volume":"138","author":"Mouffak","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.heliyon.2024.e33417_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e33417_bib18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e33417_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33417_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"O'Neill RT: use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e33417_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.heliyon.2024.e33417_bib22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","article-title":"Review of statistical methodologies for detecting drug-drug interactions using spontaneous reporting systems","volume":"10","author":"Noguchi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33417_bib23","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1002\/sim.3247","article-title":"A statistical methodology for drug-drug interaction surveillance","volume":"27","author":"Nor\u00e9n","year":"2008","journal-title":"Stat. Med."},{"key":"10.1016\/j.heliyon.2024.e33417_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.heliyon.2024.e33417_bib25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.heliyon.2024.e33417_bib26","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.heliyon.2024.e33417_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocn.2017.10.082","article-title":"Eteplirsen for paediatric patients with Duchenne muscular dystrophy: a pooled-analysis","volume":"49","author":"Randeree","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e33417_bib28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027231","article-title":"Prognosis of right ventricular systolic dysfunction in patients with Duchenne muscular dystrophy","volume":"12","author":"Fayssoil","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.heliyon.2024.e33417_bib29","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1111\/ejn.16179","article-title":"Plasticity occurs in a specific phenotype of neurons in the nucleus tractus solitarius of dystrophin gene-mutated rats","volume":"58","author":"Chikamoto","year":"2023","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.heliyon.2024.e33417_bib30","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.heliyon.2024.e33417_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024094489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024094489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:00:39Z","timestamp":1778886039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024094489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":31,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405844024094489"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33417","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events associated with eteplirsen: A disproportionality analysis using the 2016\u20132023 FAERS data","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e33417"}}